Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 7:36 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1537–1560 of 48,494 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: AS+ Clear all

Conditions: Obstructive Sleep Apnea
Interventions: Fitbit, OSA questionnaire, Polysomnography; Device · Other · Diagnostic Test
Lead sponsor: Vidya Raman; Other
Eligibility: 3 Years to 18 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Pelvic Organ Prolapse, Postoperative Pain Management, Gynecologic Surgeries
Interventions: Sitz Bath; Device
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Alcoholism, Alcohol Abuse, Hepatitis C, Liver Disease
Interventions: 3 session brief intervention with health behavior feedback, treatment as usual; Behavioral · Other
Lead sponsor: University of Washington; Other
Eligibility: 18 Years to 80 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Anesthesia, Opioid Use
Interventions: Guided mindfulness exercises, Self-administered aromatherapy, Baby aspirin, Tylenol/Acetaminophen, Pregabalin, Prednisone, Meloxicam, Prilosec, Tramadol, Voltaren, Zofran, Pepcid, Reglan, Versed, Lidocaine, Propofol, Ancef, Tranexamic Acid (TXA), Decadron, Bupivacaine hydrochloride, Toradol; Behavioral · Other · Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Elbow Fracture
Interventions: Biomet Explor Modular Radial Head Replacement; Device
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2026
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: MCI, Mild Cognitive Impairment, Mild Cognitive Impairment (MCI)
Interventions: Motivationally Enhanced Compensatory Cognitive Training for Mild Cognitive Impairment (ME-CCT-MCI), Brief Motivationally Enhanced Compensatory Cognitive Training for Mild Cognitive Impairment (bME-CCT-MCI); Behavioral
Lead sponsor: University of Florida; Other
Eligibility: 65 Years to 84 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Sickle Cell Disease
Interventions: Liver transient elastography (Fibroscan), Ferriscan, Liver biopsy in iron overloaded subjects.; Other · Procedure
Lead sponsor: University of Miami; Other
Eligibility: 10 Years to 65 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Non-small Cell Lung Cancer
Interventions: Nivolumab, Relatlimab, Pembrolizumab, Carboplatin, Pemetrexed, Cisplatin; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2032
U.S. locations: 58
States / cities: Mobile, Alabama • Tucson, Arizona • Los Angeles, California + 53 more

Conditions: Colorectal Neoplasms
Interventions: Amivantamab, Cetuximab, 5-fluorouracil, Leucovorin calcium/Levoleucovorin, Oxaliplatin, Irinotecan Hydrochloride; Biological · Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2032
U.S. locations: 81
States / cities: Gilbert, Arizona • Jonesboro, Arkansas • Springdale, Arkansas + 67 more

Conditions: Retroperitoneal Sarcoma
Interventions: Hypofractionated Proton Beam Therapy; Radiation
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Baltimore, Maryland

Conditions: Pharmacogenomics, Old Age
Interventions: Behavioral Intervention, Diagnostic Test, Data Analysis; Behavioral · Diagnostic Test · Other
Lead sponsor: Tabula Rasa HealthCare; Industry
Eligibility: 18 Years and older
Enrollment: 25 participants
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Neoplasm Malignant
Interventions: SAR566658; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 114 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2017
U.S. locations: 2
States / cities: Cincinnati, Ohio • San Antonio, Texas

Conditions: Inclusion Body Myositis
Interventions: Adipose Derived Regenerative Cells; Device
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 45 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Endothelial Dysfunction, Aging
Interventions: Aronia full spectrum - half dose, Aronia full spectrum - full dose, Placebo; Dietary Supplement
Lead sponsor: Colorado State University; Other
Eligibility: 45 Years to 75 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Fort Collins, Colorado

Conditions: Chronic Viral Hepatitis, Hepatitis B Infection
Interventions: Interview, Biospecimen Collection, Electronic Health Record Review; Other · Procedure
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years and older
Enrollment: 365 participants
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Major Depressive Disorder
Interventions: Fisher Wallace Cranial Electrotherapy Stimulator (Active Device), Fisher Wallace Cranial Electrotherapy Stimulator (Placebo Device); Device
Lead sponsor: Fisher Wallace Laboratories; Industry
Eligibility: 21 Years to 65 Years
Enrollment: 255 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 1
States / cities: New York, New York

Conditions: Osteoporosis, Renal Osteodystrophy, Kidney Transplant; Complications
Interventions: Denosumab Inj 60 mg/ml, Placebo; Drug · Other
Lead sponsor: Thomas Nickolas, MD MS; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 3
States / cities: Chicago, Illinois • Evanston, Illinois • New York, New York

Conditions: Tetraplegia, Spinal Cord Injury
Interventions: Not listed
Lead sponsor: Craig Hospital; Other
Eligibility: Not listed
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Englewood, Colorado

Conditions: Non-Hodgkin's Lymphoma
Interventions: Rituxan, 1018 ISS; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 3
States / cities: Boston, Massachusetts

Conditions: Colorectal Cancer
Interventions: PF-03446962, Regorafenib; Biological · Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Melanoma
Interventions: Ipilimumab, Corticosteroid: Betamethasone, Corticosteroid: Dexamethasone, Corticosteroid: Fludrocortisone, Corticosteroid: Hydrocortisone, Corticosteroid: Meprednisone, Corticosteroid: Methylprednisolone, Corticosteroid: Prednisolone, Corticosteroid: Prednisone, Corticosteroid: Triamcinolone; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 16 Years and older
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 14
States / cities: Scottsdale, Arizona • Duarte, California • Los Angeles, California + 11 more

Conditions: Ankylosing Spondylitis
Interventions: Sarilumab, Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 301 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 26
States / cities: Birmingham, Alabama • Anaheim, California • Los Angeles, California + 23 more

Conditions: Hematologic Neoplasms
Interventions: donor lymphocyte infusion, Cyclophosphamide, Busulfan, Mycophenolate mofetil, Fludarabine, Sirolimus; Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 12 Years to 120 Years
Enrollment: 430 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2029
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Metastatic Malignant Melanoma
Interventions: Avastin, Abraxane; Drug
Lead sponsor: Lynn E. Spitler, MD; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 2
States / cities: San Francisco, California • Santa Monica, California

Search by objective public record fields.

Comparing Fitbit® Quality of Measured Sleep to Sleep Measured by Polysomnography in the Sleep Lab

SORE Study: Sitz Baths After Urogynecologic Reconstruction

Health Behavior Feedback Study for Veterans With Hepatitis C

PROUD Study - Preventing Opioid Use Disorders

ExploR™ Modular Radial Head Data Collection

Telehealth-Adapted Compensatory Training and Intervention for Cognition

Liver Fibrosis in Sickle Cell Disease

A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%

A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer

Neoadjuvant Short-course Hypofractionated PBT for Non-metastatic RPS

Pharmacist-led Interventions to Improve Medication Use

First in Man Study of SAR566658 Administered in Patients With CA6-Positive and Refractory Solid Tumor

Inclusion Body Myositis Treatment With Celution Processed Adipose Derived Regenerative Cells

Effects of Aronia Berries on Vascular Endothelial Function and the Gut Microbiota in Middle-Aged/Older Adults

Social-environmental, Psychosocial, Behavioral, Clinical and Biological Drivers of Disparities in Liver Disease Progression Among Korean American With Chronic Hepatitis B Infection

Cranial Electrotherapy Stimulation for the Treatment of Major Depressive Disorder in Adults

The Effects of 12-months of Denosumab on Bone Density in Prevalent Kidney Transplant Recipients

Follow up Study of Diaphragm Pacing for Patients With High Tetraplegia

Study of Dynavax's 1018 ISS, Following Rituxan in Patients With B-Cell Follicular Lymphoma

Safety Study of Regorafenib With PF-03446962 to Treat Colorectal Cancer

Evaluation of Tumor Response to Ipilimumab in the Treatment of Melanoma With Brain Metastases

Dose Ranging Study to Evaluate the Efficacy and Safety of SAR153191 (REGN88) in Patients With Ankylosing Spondylitis

Donor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies

Abraxane and Avastin as Therapy for Patients With Malignant Melanoma, a Phase II Study